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Efficient backbone cyclization of linear peptides
by a recombinant asparaginyl endopeptidase
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Cyclotides are diverse plant backbone cyclized peptides that have attracted interest as
pharmaceutical scaffolds, but fundamentals of their biosynthetic origin remain elusive.
Backbone cyclization is a key enzyme-mediated step of cyclotide biosynthesis and confers a
measure of stability on the resultant cyclotide. Furthermore, cyclization would be desirable for
engineered peptides. Here we report the identification of four asparaginyl endopeptidases
(AEPs), proteases implicated in cyclization, from the cyclotide-producing plant Oldenlandia
affinis. We recombinantly express OaAEP1b and find it functions preferably as a cyclase by
coupling C-terminal cleavage of propeptide substrates with backbone cyclization.
Interestingly, OaAEP1b cannot cleave at the N-terminal site of O. affinis cyclotide precursors,
implicating additional proteases in cyclotide biosynthesis. Finally, we demonstrate the broad
utility of this enzyme by cyclization of peptides unrelated to cyclotides. We propose that
recombinant OaAEP1b is a powerful tool for use in peptide engineering applications where
increased stability of peptide products is desired.
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P
roteases are abundant throughout nature and are essential
for a wide range of cellular processes. They typically
serve to hydrolyse polypeptide chains, resulting in either
degradation of the target sequence or maturation to a biologically
active form. Less frequently, proteases can also ligate
polypeptides, producing new or alternatively spliced variants.
This unusual function has been reported for processes such
as the maturation of the lectin concanavalin A1, peptide
presentation by major histocompatibility complex class I
molecules2, and anchoring of bacterial proteins to the cell wall3.
Recently, this enzymatic transpeptidation has also been
implicated in the backbone cyclization of ribosomally
synthesized cyclic peptides4–10.
Cyclotides are a well-studied class of gene-encoded cyclic
peptides that are expressed in plants and exhibit a range of
bioactivities including insecticidal, nematicidal and molluscicidal
activity against agricultural pests11–14. Structurally, they are
characterized by a cyclic cystine knot motif that confers
exceptional stability. Importantly, this stable framework can be
used as a pharmaceutical scaffold, and bioactive sequences have
been successfully grafted into cyclotides15. Backbone cyclization
can also endow peptides with oral bioavailability, suggesting that
this modification might find broad application in peptide drug
engineering16–18. However, in vitro cyclization of synthetic
peptides is challenging and the limited availability of enzymes
capable of this process is a hurdle to large-scale production19,20.
Furthermore, expression yields of cyclotides in transgenic
plants that are not native cyclotide producers is poor, impeding
transfer of agriculturally relevant bioactivities to other plants8,21.
The mechanism of enzymatic cyclization intrinsic to
cyclotide biosynthesis is poorly understood. Elucidating it will
be important for the realization of the pharmaceutical
and agricultural potential of cyclotides and for increasing
the cyclization efficiency of unrelated ‘designed’ bioactive
peptides.
Cyclotides are produced as precursors in which the cyclotide
sequence is flanked by N- and C-terminal propeptides (Fig. 1).
It is thought that enzymatic removal of the N-terminal
propeptide precedes the final maturation step of C-terminal
propeptide cleavage and ligation of the free N- and C-termini8,21.
Only four native cyclases have been identified to date and the best
characterized of these is the serine protease PatG, which cyclizes
the bacterial cyanobactins4–7. In plants, the serine protease PCY1
cyclizes the segetalins; cyclic peptides from the Caryophyllaceae4.
However, in the two other classes of plant-derived cyclic peptides
(cyclotides and the PawS-derived cyclic peptides), strong Asx
sequence conservation at the C-terminal P1 site implicates as
possible cyclases the asparaginyl endopeptidases (AEPs), a group
of cysteine proteases also known as vacuolar processing enzymes
or Legumains, and this hypothesis is supported by studies in
transgenic plants8,9,21,22.
Recently, an AEP (butelase 1) was isolated from the cyclotide-
producing plant Clitoria ternatea and shown to cyclize a modified
precursor of the prototypical cyclotide, kalata B1 (kB1) from
Oldenlandia affinis, however, recombinant expression of func-
tionally active butelase 1 has not been achieved, limiting its
application5. Only one AEP with any cyclizing ability has been
produced recombinantly, and this enzyme was highly inefficient,
producing mainly hydrolysed substrate10. Here we report the
identification, recombinant production and characterization of an
O. affinis AEP that preferentially functions as a cyclase. The
enzyme can cyclize native kalata substrate precursors and the
unrelated anti-malarial peptide, R1, at close to 100% efficiency.
This AEP releases the C-terminal propeptide of kB1, but it does
not mediate the N-terminal processing event, which must occur
first if efficient cyclization is to take place. Moreover, its specificity
for model peptides mirrors the sequence requirements for
cyclization of kB1 in transgenic plants, supporting a native
function in the maturation of O. affinis cyclotides8,21.
Results
Identification and recombinant expression of O. affinis AEPs.
Three expressed AEP isoforms were identified in an O. affinis
complementary DNA library (OaAEP1-3) and a fourth sequence,
with a single nucleotide change from OaAEP1 (resulting in a
Glu371Val variant), was identified from genomic DNA
(OaAEP1b) (Fig. 2a; Supplementary Fig. 1). The four isoforms
share at least 77% identity at the protein level, as determined by
pairwise protein alignments. When compared with butelase 1,
64–69% identity was observed, whereas identity with human
legumain was 49–53%.
OaAEP1b was expressed in Escherichia coli as a His6-ubiquitin-
AEP1b fusion protein (Supplementary Fig. 2a). AEPs are usually
produced as zymogens that are self-processed at low pH to their
mature, active form23–25. Consistent with this processing, activity
of rOaAEP1b against an internally quenched fluorescent (IQF)
peptide representing the native C-terminal processing site in kB1
(Table 1; wildtype (wt)) was markedly increased following
incubation at pH 4.5 (Fig. 2b). After purification, a dominant
band of B32 kDa was evident by reducing SDS–polyacrylamide
gel electrophoresis (PAGE) and confirmed to be rOaAEP1b by
Western blotting (Fig. 2c; Supplementary Fig. 2b). The average
total protein yield from two independent experiments was
B1.8mg l 1 after activation and purification, however batch to
batch variation in purity was observed. Although glycosylation of
some AEPs has been reported26, the production of an active form
in E. coli confirms that this is not a requirement for activity of
O. affinis AEP1b.
Mass spectrometry (MS)/MS sequencing of peptide fragments
generated from tryptic, chymotryptic or endoGlu-C digestion of the
activated enzyme identified several peptide fragments with non-
canonical cleavage sites, suggesting that they may be derived from
rOaAEP1b auto-processing events (Supplementary Fig. 2). This
allowed Asp52 to be assigned as the likely N-terminal auto-
processing site and Asp328, Asn329, Asp334, Asn336, Asp349 and/
or Asp351 as potential C-terminal processing sites (Fig. 2a;
Supplementary Fig. 2). No peptides downstream of Asp351 were
identified, indicating that the activation was essentially complete and
that the C-terminal domain (Leu352–Pro474) was removed during
the post-activation purification step. The theoretical mass of the
processed forms (30.4–32.8 kDa) is in good agreement with that
determined by SDS–PAGE/Western blotting (Fig. 2c).
Consistent with cysteine proteases of this class, rOaAEP1b was
inhibited by iodoacetamide (1mM), but was not affected by
E64 (250 mM) or pepstatin A (10 mM) (Supplementary Fig. 3).
Ac-YVAD-CHO (500 mM), a caspase-1 inhibitor reported to also
ER SP NTPP Cyclotide domain (Gly1-Asn29) CTPP
CTRN GLPS
P4–P1P1′–P4′
LQLK GLPV
P1′′–P4′′
Figure 1 | Schematic representation of the Oak1 gene. The precursor
protein encoded by the Oak1 gene is proteolytically processed to mature
kB1. . indicates the N- and C-terminal processing sites. rOaAEP1b targets
the C-terminal processing site. The C-terminal P1/P10 - P4/P40 sites are
indicated. P10 0-P40 0 denote the N-terminal residues that replace the P10-P40
residues on release of the C-terminal propeptide. CTPP, C-terminal
propeptide; ER SP, endoplasmic reticulum signal peptide; NTPP, N-terminal
propeptide.
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inhibit AEPs27, was a poor inhibitor of the recombinant enzyme
suggesting that at least some P0 residues are important for active
site targeting.
Substrate specificity. The activity of rOaAEP1b against IQF
peptides representing wt and mutant versions of the native kB1
C-terminal cleavage site was determined (Table 1; Supplementary
Fig. 4a). Along with the strict P1 Asx specificity characteristic of
AEPs24, rOaAEP1b exhibited strong P20 selectivity since after
Leu31Ala substitution within the IQF peptide barely any
hydrolysis was observed. This observation is consistent with the
lack of cyclic product generated when the corresponding
mutation was introduced in planta21. Kinetic parameters (Vmax,
Km and kcat) are reported where applicable (Table 1). The
turnover rates (kcat) reported here (B0.06–1.6min 1) are much
slower than that reported for recombinant human legumain
assayed against a small substrate (B8 s 1) (ref. 28). This is not
unexpected given that rOaAEP1b prefers to carry out cyclization,
rather than the hydrolysis being measured here. Supporting the
observed P20 selectivity, rOaAEP1b was unable to cleave the
generic AEP substrate Z-AAN-MCA (Supplementary Fig. 5).
The substrate specificity of rOaAEP1b was compared with that
of recombinant human legumain (rhuLEG; Supplementary
Fig. 4b)29. A stringent P1 Asx requirement was again observed;
however, in contrast to rOaAEP1b, rhuLEG cleaved the Leu31Ala
substrate at a rate similar to the wt substrate, demonstrating that
P20 specificity is not a feature of all AEPs.
Cyclization of kB1 precursors. To explore the cyclization ability
of rOaAEP1b, processing of correctly folded (as determined by
NMR) synthetic kB1 precursors was assessed by MS. When
incubated with the wt kB1 precursor carrying the native
C-terminal pro-hepta-peptide (GLPSLAA), the active enzyme
produced a peptide of 2,891.2Da (monoisotopic, [MþH]þ ),
consistent with the expected mass of mature, cyclic kB1 (Fig. 3a).
This product was confirmed to be identical to native kB1
by reversed phase-high performance liquid chromatography
(RP-HPLC) co-elution (Supplementary Fig. 6) and one- and
two-dimensional-NMR experiments (Supplementary Fig. 7).
Kinetic parameters (±s.e.m.) for the processing of the wt kB1
precursor were 0.53 (±0.1) s-1 for kcat, 212 (±76) mM for Km
and 2,500M 1 s 1 for kcat/Km as determined from a
Michaelis–Menten plot (Supplementary Fig. 8). While the turn-
over rate (kcat) is lower than that reported for the plant-derived
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Figure 2 | Expression of active rOaAEP1b in E. coli. (a) Sequence of
OaAEP1b predicted from O. affinis genomic DNA. Predicted ER signal
sequence shown in red; N-terminal propeptide shown in blue; the putative
signal peptidase cleavage site is indicated by r and autocatalytic
processing sites by .. The mature OaAEP1 cyclase domain is underlined
and the C-terminal auto-processing region is indicated with broken
underline. The putative catalytic dyad is shown in bold and labelled with *.
(b) An rOaAEP1-containing anion exchange fraction pre-and post-activation
at pH 4.5 (5 h, 37 C) was tested for activity against the wt IQF peptide
(14mM). Baseline fluorescence from a no substrate control has been
subtracted and the relative fluorescence intensity (RFU) at t¼ 90min is
reported. The average of two technical replicates is shown and error bars
report the range (c) Activated rOaAEP1b purified by cation exchange was
analysed by SDS–PAGE and (i) Instant blue staining or (ii) Western blotting
with anti-OaAEP1b (residues D47–P474) polyclonal rabbit serum.
Table 1 | Kinetic parameters of IQF peptide cleavage by rOaVPE1b.
IQF peptide Sequence* Vmax (nmoles min
-1mg-1 protein) (±s.e.m.)w Km (lM) (±s.e.m.)w kcat (min-1) (±s.e.m.)w,z
wt Abz-STRNkGLPS-Y(3NO2) 51.3 (±5.8) 55.0 (±6.4) 1.6 (±0.2)
R28A Abz-STANkGLPS-Y(3NO2) 6.9 (±0.6) 13.0 (±2.4) 0.2 (±0.02)
R28K Abz-STKNkGLPS-Y(3NO2) 29.3 (±3.5) 42.0 (±4.0) 0.9 (±0.1)
N29A Abz-STRAkGLPS-Y(3NO2) NA
y  
N29Q Abz-STRQkGLPS-Y(3NO2) NA
y  
N29D Abz-STRDkGLPS-Y(3NO2) B2|| ND|| B0.06||
G30A Abz-STRNkALPS-Y(3NO2) 51.0 (±2.0) 29.0 (±1.4) 1.6 (±0.07)
G30S Abz-STRNkSLPS-Y(3NO2) 35.5 (±2.7) 31.4 (±2.5) 1.1 (±0.08)
L31A Abz-STRNkGAPS-Y(3NO2) NA
y  
L31I Abz-STRNkGIPS-Y(3NO2) ND
z NDz NDz
IQF, internally quenched fluorescent; NA, no activity; ND, not determined.
*IQF peptide residues are numbered according to their position within the native kB1 precursor, where the mature cyclotide incorporates Gly1-Asn29; native Cys26 is substituted with Ser to avoid unpaired
Cys residues.
wNZ 3;±standard error of the mean (s.e.m.)
zkcat is a conservative estimate assuming that the total concentration of active enzyme is equal to the total protein concentration in the enzyme preparation and an enzyme mass of 32 kDa.
yNo activity detected under the conditions tested (up to 80 mM substrate; up to 6 h incubation).
||Low Vmax precluded accurate estimation of kinetic parameters.
zKm above the range of the substrate concentrations used in this analysis precluded accurate estimation of kinetic parameters.
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butelase 1 (17.08 s 1; ref. 5), it is far higher than that of the
recombinantly expressed cyclase PatG (1 per day; ref. 7).
To determine if rOaAEP1b could also carry out the N-terminal
processing required for cyclotide maturation, a kB1 precursor was
tested that contained the folded cyclotide domain flanked by four
residues from each of the N- and C-terminal propeptides
(Fig. 3b). No N-terminal processing was observed, indicating
that this processing is conducted by an enzyme other than
OaAEP1b. Although the bulk of the precursor remained intact
after 20.5 h, the predominant processing product was a linear
peptide lacking the C-terminal propeptide, demonstrating that
correct N-terminal processing must occur before cyclization.
Interestingly, a mass corresponding to a cyclized version of the
C-terminally processed peptide (that is, C-terminal propeptide
residues released, N-terminal propeptide residues remaining) was
also observed, although this was the least abundant product.
Processing of modified cyclotide precursors. To further probe
cyclization requirements, we tested rOaAEP1b-mediated
processing of modified kB1 and kB2 precursors over time (Fig. 4).
When presented within an IQF peptide, the Leu31Ala substrate
analogue was not hydrolysed by rOaAEP1b (Table 1). However,
the same substitution within the kB1 precursor did not preclude
cyclization by rOaAEP1b, although this version was cyclized far
more slowly than the wt precursor (Fig. 4a,b). Surprisingly, the
presence of disulfide bonds in the cyclotide precursors is not a
requirement for cyclization since a kB1 substrate analogue in
which all six cysteines were substituted with serines was also
efficiently cyclized (Fig. 4c). The absence of a defined kB1-like
structure in the kB16xS mutant was confirmed by NMR
spectroscopy (Supplementary Fig. 7c). Similarly, a kB2 linear
precursor with the same Cys-Ser substitutions was also
efficiently cyclized, confirming that enzyme activity is not specific
to individual cyclotides (Fig. 4d).
In cysteine protease-mediated peptide bond hydrolysis,
nucleophilic attack of a water molecule is required to resolve
the acyl-enzyme thioester intermediate. However, during peptide
cyclization (or transpeptidation) the substrate’s N-terminal amine
is postulated to function as a competing nucleophile, facilitating
aminolysis of the reactive thioester intermediate30. Accordingly, a
kB1 precursor with an acetyl-capped N-terminal amine was
processed only to a linear peptide lacking the C-terminal
propeptide (Fig. 4e). This hydrolysis occurred at a slower rate
than cyclization of the wt precursor (compare with Fig. 4a).
Water can therefore access the active site of rOaAEP1b, but
cyclization is favoured over hydrolysis in the presence of an
appropriately positioned nucleophile.
Water is excluded during cyclization. An alternative ligation
mechanism, distinct from transpeptidation, was recently
proposed for huLEG31). In that mechanism, initial hydrolysis of
the C-terminal propeptide is followed by a separate ligation event
requiring a C-terminal Asn residue in the substrate. To
distinguish between these mechanisms in the case of
rOaAEP1b, reactions were carried out in the presence of 18O-
labelled water and the products were analysed by high-resolution
MS. An isotopic shift consistent with the incorporation of 18O
was evident following enzymatic hydrolysis of the N-terminal
acetylated kB1 precursor to give a linear product (Fig. 5a).
However, there was no isotopic shift after processing of the wt
precursor to a cyclic product, suggesting that hydrolysis is
unlikely to play a role in cyclization by rOaAEP1b (Fig. 5a).
Cyc
(2,891.2)
+6 Da
2,800 2,900 3,000 3,100 3,200 3,300 3,400 3,500
Pre
m/z
3,200 3,300 3,400 3,500 3,600 3,700 3,800 3,900
m/z
Pre
(3,792.6)
Lin
–99 Da
Lin
(3438.6)
Cyc
(3420.6)
a
b
Figure 3 | Enzymatic processing products of linear kB1 precursors. (a) MALDI MS profile of a kB1 precursor (kB1wt) containing the C-terminal propeptide
in the presence of rOaAEP1b (22 h incubation). The þ6Da peak was observed only in the presence of reducing agent and corresponds to the reduced form
of cyclic kB1. (b) MALDI MS profile of a kB1 precursor (kB1C&N) containing four C-terminal propeptide residues and four N-terminal propeptide residues in
the presence of rOaAEP1b (20.5 h incubation). A side product originating from chemical synthesis likely represents a Val deletion (99Da). Data are
representative of at least two technical replicates. X, benzoylphenylalanine. * denotes rOaAEP1b cleavage site. Observed monoisotopic masses (Da;
[MþH]þ ) for dominant peaks are listed. Cyc, cyclic product; Lin, linear product; Pre, linear precursor.
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rOaAEP1b can cyclise an unrelated peptide. We also
investigated cyclization of other substrates structurally
unrelated to cyclotides by rOaAEP1b, focussing on the
anti-malarial peptide R1 (refs 32,33). This peptide was efficiently
cyclized following the addition of N- and C-terminal AEP
recognition sequences (Fig. 6a). Sequential trimming of the
added recognition residues revealed that cyclization could be
achieved following the addition of only a C-terminal Asn–Gly–
Leu motif (although some linear product was also produced
from this precursor) (Figs 6a–d). Lys and Gln were also
accepted in place of Gly at the N terminus (Figs 6e–f) with little
impact on yield at the time point tested. No processing of
either the native R1 peptide or a modified R1 carrying the
N-terminal Gly–Leu motif with only an Asn at the C terminus
was observed (Supplementary Fig. 9). Subsequent digestion
with endoGlu-C confirmed that, in all cases, rOaAEP1b
processing produced cyclic peptide (Supplementary Fig. 10).
Evidence of an additional, linear, rOaAEP1b-generated
cleavage product was only observed for the R1 variant without
any N-terminal flanking residues (Fig. 6d; Supplementary
Fig. 10c).
kB1wt kB1L31A kB16×S kB26×S kB1acetyl
1 h
2,891.2
3,476.9 2,801.5
3,428.9
2,864.5 3,560.9
2,951.4
3,534.2
5 h
2,891.4
Cy
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Figure 4 | Modified linear kB1 and kB2 precursors are cyclized at different rates. MALDI MS spectra of (a) kB1wt, (b) kB1L31A, (c) kB16xS, (d) kB26xS and
(e) kB1acetyl cyclotide precursors at 1, 5 and 22 h post-enzyme addition. Data are representative of three technical replicates. * denotes rOaAEP1b cleavage
site. Observed monoisotopic masses (Da; [MþH]þ ) for dominant peaks are listed. Boxed inset at the 22 h time point zooms in on the region containing
the processing product. Approximate positions of the monoisotopic mass of processed products is indicated by y . Cyc, cyclic product; Lin, linear product;
Pre, linear precursor.
Hydrolysed product
2,950.2 2,955.2
m/z
+ H218O
– H218O
m/z
2,890.1
Cyclic product
2,895.1
a b
Figure 5 | Enzymatic cyclization excludes water. MALDI MS profile of the
enzymatic processing products of (a) kB1acetyl and (b) kB1wt linear
precursors in the presence and absence of 18O-labelled water. An isotope
shift indicative of 18O incorporation only occurs during hydrolysis. Observed
masses of two isotopic peaks (Da; [MþH]þ ) are indicated. Data are
representative of three technical replicates.
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Discussion
This study reports the cloning of four AEPs from the cyclotide-
producing plant O. affinis; one of which was recombinantly
expressed. The recombinant enzyme required self-processing to
produce the active product: a cyclase that preferentially and
efficiently couples C-terminal processing with C- and N-terminal
ligation of linear O. affinis cyclotide precursors. Furthermore, this
cyclizing ability was highly efficient when transferred to an
unrelated anti-malarial peptide, demonstrating broad applicabil-
ity in peptide engineering.
Consistent with other auto-inhibited proteases, rOaAEP1b
required proteolytic activation to achieve maximum activity
(Fig. 2b). The observed N-terminal auto-processing site (Asp52)
is consistent with other experimentally validated N-terminal
auto-processing sites identified in jack bean AEP34, butelase 1
(ref. 5) and human legumain28,35 (Fig. 2a, Supplementary Fig. 1).
In contrast, six potential C-terminal auto-processing sites
(Asp328/334/349/351, Asn329/336) were observed within a
region particularly rich in Asn/Asp residues (324–351). This
finding is in agreement with the multiple C-terminal maturation
steps recently described for rhuLEG28,35. Regardless of which of
these sites is relevant in planta, the instability of active AEPs
above pH 6 (refs 28,29,36) will likely preclude direct production
of active enzyme in E. coli. Activated rOaAEP1b proteolytically
removed the C-terminal (but not N-terminal) propeptide of a
kB1 precursor and resolved the acyl-intermediate in a
hydrolysis-independent manner, generating a backbone cyclized
product (Figs 3 and 5). rOaAEP1b could also hydrolyse
precursors lacking a free N-terminal amine to produce linear
products, albeit at a slower rate. Although it is unknown if
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Figure 6 | Flanking sequence requirements for cyclization of a model peptide by rOaAEP1. (a–f). MALDI MS spectra of the R1 peptide
(VFAEFLPLFSKFGSRMHILK) with various flanking sequences 22 h post addition of rOaAEP1b. Bold residues, flanking sequences. *denotes rOaAEP1b
cleavage site. Observed monoiosotopic masses (Da; [MþH]þ ) are listed. þ 22Da and  16Da peaks present in some precursor and product spectra are
likely to represent Naþ adducts and a synthesis-derived modification respectively. Data are representative of three technical replicates. Cyc, cyclic product;
Lin, linear product; Pre, linear precursor.
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OaAEP1b performs both these cyclase and protease activities
in vivo, the observed preference for cyclization over hydrolysis
suggests that it probably functions predominantly as a cyclase.
Dual protease/ligase capabilities have been reported for PatG37,
a serine protease involved in cyclic peptide production in
cyanobacteria, and more recently for human legumain31.
Separate mechanistic pathways for hydrolysis and ligation have
been proposed for human legumain: proteolysis proceeds via
hydrolysis of a cysteinyl-thioester enzyme intermediate, whereas
peptide ligation occurs via activation of the free peptidyl-a-
carboxylate through transient formation of an enzyme-linked
anhydride intermediate that is subsequently resolved via
aminolysis31. The catalytically critical residue for this
mechanism of ligation, Asp188, is conserved in OaAEP1b, but
several lines of evidence preclude a role for this pathway in
OaAEP1b-mediated peptide cyclization. First, rOaAEP1b cannot
cyclize peptides carrying a free C-terminal Asn, the minimal
proposed substrate requirement in the alternative pathway
(Supplementary Fig. 9). Second, our H218O experiments
demonstrate the absence of 18O incorporation into the cyclized
product, which strongly indicates that cyclization does not follow
a hydrolysis/ligation mechanism as proposed in the alternative
pathway (Fig. 5). Third, our MS/MS data for rOaAEP1b show no
evidence of a reactive succinimide enzyme intermediate required
for formation of the substrate–enzyme anhydrides31. Hence, our
mechanistic data are in agreement with the traditional concerted
mechanism, in which some of the energy from the (exergonic)
cleavage of the C-terminal Asn-propeptide bond is preserved in
the form of a thioester intermediate and used to overcome the
energetically unfavourable (endergonic) peptide bond formation
(cyclization) in the second step. However, alternative mechanisms
may still play a role in cyclization mediated by other AEPs or with
alternative substrates.
In the context of this established mechanism, C- and
N-terminal proximity was thought to be crucial for cyclization
to be favoured over hydrolysis8. Here we show that
pre-organization of C- and N-termini in the substrate is not
required by rOaAEP1b since unconstrained cyclotide precursors
lacking the characteristic disulfide-bonded structure are efficiently
cyclized (Fig. 4). Furthermore, rOaAEP1b can cyclize an
anti-malarial peptide that is structurally and functionally
unrelated to cyclotides following the addition of short flanking
sequences (Fig. 6). These findings are consistent with the limited
structural and/or sequence requirements imposed by other native
cyclases on their substrates4,5,7 Conceivably, polypeptides of
diverse composition and length may be cyclized by rOaAEP1b,
provided that association of the C- and N-termini is not sterically
hindered.
The application of this technology is limited to peptides that
can retain activity following incorporation of the additional
residues required for AEP-mediated processing. While rOaAEP1b
can cyclize a model peptide with only a single non-native residue
incorporated to the mature peptide, this is at the cost of
cyclization efficiency (Fig. 6d). Understanding the interplay
between the sequence requirements for efficient cyclization and
retention of bioactivity for a given target peptide will be crucial to
realizing the potential of AEP-mediated cyclization. Importantly,
the estimated turnover rate of rOaAEP1b (kcat, 0.53 s 1;
Supplementary Fig. 8) is multiple orders of magnitude higher
than the recombinantly produced cyclase PatG (1 d 1; ref. 7),
supporting its widespread application in peptide engineering.
In a previous study, a conserved tripeptide motif C terminal to
both the N- and C-terminal cyclotide processing sites was
identified through cyclotide sequence analysis8. This motif is
Gly–Leu–Pro in the kB1 sequence, and its importance for efficient
cyclization is supported by mutagenesis studies in transgenic
plants8,21. The protease specificity of rOaAEP1b reported here
against IQF peptides mirrors these requirements (Table 1). At the
C-terminal processing site, the P1 Asn and P20 Leu are
particularly well-conserved, and both were crucial for both in
planta cyclization and in vitro cleavage of model peptides.
However, over the longer incubation period of the cyclization
assays, a kB1 precursor with a Leu31Ala mutation was still
enzymatically processed to a cyclic product (Fig. 4). It was
initially proposed that the conserved Leu residue at the P20
position of cyclotides was important for preventing water from
accessing the active site during cyclization. However the observed
cyclization of the kB1 Leu31Ala mutant suggests that the role of a
conserved bulky hydrophobic residue at the P20 position is only to
promote appropriate enzyme–substrate interaction. Congruent
with this hypothesis, the absence of a P20 residue renders
substrates poor targets of both rOaAEP1b (cyclization and
hydrolysis; Fig. 6c; Supplementary Fig. 5) and butelase 1
(at least for hydrolysis)5. In summary, our results suggest a
cyclization model in which the cleaved C-terminal propeptide
retains sufficient affinity to remain bound to the active site until it
is displaced by the incoming N terminus of the peptide, finally
leading to cyclization by resolving the acyl intermediate8,38.
This P20 requirement is not characteristic of all AEPs9,34,39 and
might be a predictor of cyclization ability within this protease
family. Indeed, in extracts from C. ternatea, protein fractions that
were active against the generic AEP substrate Z-AAN-MCA
(which does not contain a P20 residue) did not contain the
cyclizing enzyme and, conversely, the butelase 1 containing
fraction did not display activity against this substrate5. Here we
report the presence of four unique AEP sequences in O. affinis
(Fig. 2a; Supplementary Fig. 1), and demonstrate that one
(OaAEP1b) is capable of cyclizing O. affinis cyclotide precursors.
Further work will investigate whether all, or a subset of, O. affinis
AEPs (at least two more of which should exist to explain all the
AEP contig sequences observed) exhibit this function and
whether their substrate specificity is an accurate predictor of
cyclization ability.
The constraints on the sequence of the incoming N terminus
may not be very stringent. At least two residues with different
properties are accepted in place of Gly at the P100 position by
rOaAEP1b with comparable yields of cyclic product under the
conditions tested (Fig. 6e,f). Butelase 1 and Pat G also exhibit
promiscuity in this region5,37. Interestingly, Gly1 is highly
conserved across cyclotides from different plant species, raising
the possibility that selection at this position is not driven by AEP
cyclase specificity. In transgenic plants, more stringent requisites
were observed and no cyclic product was made from kB1
precursors with a conservative Gly1Ala mutation8. Because AEP
cannot liberate the N-terminal propeptide, we hypothesize that
selection at Gly1 might be driven by the putative N-terminal
processing enzyme. Further analysis will be necessary to
determine if this reflects differences in the enzyme homologues
being assayed (that is, AEPs from the model plant Nicotiana
benthamiana compared with AEPs from native cyclotide
producers) or experimental conditions.
In conclusion, this study unequivocally demonstrates the
involvement of an AEP in maturation of native O. affinis
cyclotides, advancing our understanding of the biosynthesis of
this important class of cyclic peptides. Furthermore, the
promiscuous yet highly efficient nature of this recombinantly
produced enzyme highlights its exciting potential value as a
biological tool for cyclization of a range of bioactive peptides.
Methods
Peptide substrates and inhibitors. IQF peptides containing an N-terminal
o-aminobenzoic acid (Abz) group and a C-terminal 3-nitrotyrosine (Y[3NO2])
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were synthesized by Genscript at490% purity. Control IQF peptides representing
the predicted cleavage products of the wt peptide (Abz-STRN; GLPS-Y(3NO2)
were also synthesized by Genscript at 490% purity. All IQF peptides were solu-
bilized in 25% (v/v) acetonitrile:water. The fluorogenic peptide substrate Z-AAN-
MCA (where Z is carboxybenzyl; MCA is 7-amido-4-methylcoumarin) and the
caspase inhibitor Ac-YVAD-CHO (where Ac, acetyl; CHO, aldehyde) were sup-
plied by the Peptide Institute and solubilized in dimethyl sulfoxide. The linear
cyclotide precursor peptides kB1wt, kB1C&N, kB1L31A and kB1acetyl were chemically
synthesized in-house by standard Fmoc solid-phase peptide synthesis. Folding and
disulfide formation was carried out by incubating the reduced peptides in folding
buffer (100mM ammonium bicarbonate, 50% isopropanol, 2mM reduced
glutathione, 1mM oxidized glutathione, pH 8.2) for 3 days40. The products were
isolated by RP-HPLC at 495% purity and characterized by high-resolution MS
and NMR spectroscopy. Peptides kB16xS and kB26xS as well as R1 and its
derivatives were supplied by Genscript at 485% purity, as determined by
RP-HPLC and MS. Peptides were dissolved in ultrapure water before analysis.
O. affinis transcriptome. Total RNA was extracted from O. affinis root, leaf and
seedling tissues using a phenol extraction method. Plant material was frozen in
liquid nitrogen and ground to a fine powder, which was then resuspended in buffer
(0.1M Tris-HCl pH 8.0, 5mM EDTA, 0.1M NaCl, 0.5% SDS, 1% 2-mercap-
toethanol), extracted twice with 1:1 phenol:chloroform and precipitated by addition
of isopropanol. The pellets were dissolved in 0.5ml water and RNA was pre-
cipitated overnight at 4 C by addition of 4M lithium chloride. The extracted RNA
of each tissue was analysed by GeneWorks using the Illumina GAIIx platform. In
total, 69.3 million 75 bp paired-end reads were generated. Reads were filtered with a
phred confidence value of Q37 and assembled into contigs using Oases41 with
k-mer ranging from 41–67. The assemblies were merged using cd-hit-est42,
resulting in 270,000 contigs. Statistics on the depth of sequencing were made
by aligning the reads of each tissue on the contigs using BWA43. All the
sequences, including one AEP, previously identified from an EST library of O.
affinis were present among the contigs44. Homologues of this AEP sequence were
searched using BLAST45 in the contig library using a maximum E-value of 1e-20,
resulting in the identification of 371 putative AEP transcripts. These sequences
could then be clustered in 13 groups sharing at least 90% sequence identity
using cd-hit42.
OaAEP1-3 cloning. Full-length AEP transcripts from the O. affinis transcriptome
assembly were used to design a set of primers. A single degenerate forward primer
(OaAEPdegen-F, 50-ATG GTT CGA TAT CYC GCC GG-30) was sufficient to
amplify all sequences since variability within the extreme 50 region of each full-
length transcript was limited to a single nucleotide position. Three reverse primers
(OaAEP1-R, 50-TCA TGA ACT AAA TCC TCC ATG GAA AGA GC-30 ;
OaAEP2-R, 50-TTA TGC ACT GAA TCC TTT ATG GAG GG-30 ; OaAEP3-R
50-TTA TGC ACT GAA TCC TCC ATC G-30) were designed with the aid of
Primer 3 (ref. 46). Each primer set successfully amplified an AEP sequence.
To clone expressed OaAEPs, total RNA was extracted from O. affinis leaves and
shoots using TRIzol (Life Technologies) and was reverse transcribed with
SuperScript III reverse transcriptase (Life Technologies) according to the
manufacturer’s instructions11. Target sequences were amplified from the resulting
complementary DNA using Phusion High Fidelity Polymerase (New England
BioLabs) and the primers described above under the recommended reaction
conditions. Gel extracted PCR products were dA-tailed by incubation with
Invitrogen Taq Polymerase (Life Technologies) and 0.5 ml 10mM dA in the
supplied buffer. The processed products were cloned into pCR8-TOPO (Life
Technologies) and transformed into E. coli. Purified DNA from clones that were
PCR positive for an AEP insert were sent for Sanger sequencing at the Australian
Genome Research Facility (www.agrf.org). Coding sequences have been deposited
in Genbank (accession codes: OaAEP1 (KR259377), OaAEP2 (KR259378),
OaAEP3 (KR259379)).
In an alternative approach, genomic DNA was extracted from O. affinis leaf
tissue using a DNeasy Plant Mini Kit according to the manufacturer’s instructions.
PCR amplification from this DNA used primers specifically targeting the OaAEP1
nucleotide sequence. Gel extracted product was dA-tailed as above, cloned into the
TOPO vector and transformed into E. coli. Sequencing of PCR-positive clones
identified a fourth sequence with a single amino acid change from OaAEP1
(OaAEP1b).
Antibodies. Polyclonal anti-OaAEP1b rabbit serum was generated by immunizing
a New Zealand White rabbit with a denatured, inactive form of OaAEP1b (residues
D47–P474) that was produced recombinantly in E. coli. The rabbit received three
doses, four weeks apart, of 150mg of antigen in 50% (v/v) PBS and Freund’s
incomplete adjuvant. Serum was obtained 2 weeks after the final dose and used at a
1:2,000 dilution for Western blotting.
Recombinant expression of O. affinis AEP1b (rOaAEP1b). Initial trials to
produce active O. affinis AEP1b based on predicted N- and C-terminal processing
sites (residues D47–D420) were unsuccessful and subsequent expression attempts
incorporated both N- and C-terminal prodomains. DNA encoding full-length
O. affinis AEP1b without the putative signalling domain (residues A24-P474) was
inserted into the pHUE vector47 to give a His6-ubiquitin-OaAEP1b fusion protein
construct (Supplementary Fig. 2) and introduced into T7 shuffle E. coli cells
(New England BioLabs). Transformed cells were grown at 30 C in superbroth
(3.5% tryptone (w/v), 2% yeast extract (w/v), 1% glucose (w/v), 90mM NaCl, 5mM
NaOH) to mid-log phase; the temperature was then reduced to 16 C and
expression was induced with isopropyl –D-1-thiogalactopyranoside (0.4mM)
for B20 h. Cells were harvested by centrifugation and resuspended in
non-denaturing lysis buffer (50mM Tris-HCl, 150mM NaCl, 0.1% triton X 100,
1mM EDTA, pH 7). Lysis was promoted by a total of five freeze/thaw cycles and
the addition of lysozyme (hen egg white; 0.4mgml 1). DNase (bovine pancreas;
40 mgml 1) and MgCl2 (0.4M) were also added. Cellular debris was removed by
centrifugation and the lysate was stored at  80 C until required.
Purification and activation of rOaAEP1b. Lysate containing expressed rOaAEP1b
was filtered through a 0.1 mm glass fibre filter before being diluted 1:8 in buffer A
(20mM bis-Tris, 0.2M NaCl, pH 7) and loaded onto two 5ml HiTrap Q Sepharose
high performance columns connected in series (GE Healthcare; 1.6–3.1ml
undiluted lysate per millilitre resin). Bound proteins were eluted with a continuous
salt gradient (0–30% buffer B (20mM bis-Tris, 2M NaCl, pH 7); 15 column
volumes) and AEP-positive fractions identified by Western blotting (anti-OaAEP1b
rabbit serum (1:2,000); peroxidase-conjugated anti-rabbit IgG (GE Healthcare
NA934; 1:5000)). To self-activate rOaAEP1b, EDTA (1mM) and Tris(2-carbox-
yethyl)phosphine hydrochloride (0.5mM) were added, the pH was adjusted to 4.5
with glacial acetic acid and the protein pool was incubated for 5 h at 37 C. Protein
precipitation at this pH allowed removal of the bulk of the contaminating proteins
by centrifugation. The remaining protein was filtered (0.22 mm), diluted 1:8 in
buffer A2 (50mM acetate, pH 4) then captured on a 1ml HiTrap SP Sepharose
high performance column (GE Healthcare). Bound proteins were eluted with a salt
gradient (0–100% buffer B2 (50mM acetate, 1M NaCl, pH 4); 10 column volumes)
and AEP-positive fractions were pooled. The final product was analysed by MS and
reducing SDS–PAGE followed by Western blotting and staining with Instant blue
(Expedeon). The total concentration of protein was estimated by bicinchoninic acid
assay according to the manufacturer’s instructions.
Identification of the auto-processing sites of rOaAEP1b. Aliquots of rOaAEP1b
(5 ml) were diluted 1:1 with either 100mM ammonium bicarbonate pH 8.0 (trypsin,
chymotrypsin) or 100mM ammonium phosphate pH 8.0 (endoGlu-C) and
enzymatically digested with endoGlu-C, trypsin or chymotrypsin (100 ng ml 1).
Cleavages were conducted over 16 h at 37 C (endoGlu-C, trypsin) or 30 C
(chymotrypsin). Injections of each digest (5 ml) were introduced to a Shimadzu
nanoLC delivering a linear acetonitrile gradient at a flow rate of 500 nlmin 1 for
reversed-phase separation on a C18 Zorbax column (Agilent 300SB-C18, 3.5 mm
particle size, 150mm 100mm). Column eluate was interfaced directly with a
5600 TripleTOF LC-MS/MS instrument (AB SCIEX, Canada) equipped with
a nanoelectrospray ionization source.
Tandem MS data were generated in Information Dependent Acquisition
experiments, wherein full-scan TOF-MS spectra were acquired for 250ms over m/z
350–1,800, and the 20 most intense signals with charge state þ 2 to þ 5 were
selected for product ion scans of duration 50ms over m/z 80–1,400. Data were
acquired and processed using the Analyst TF 1.6 software (AB SCIEX, Canada).
Automated protein identification was performed in ProteinPilot 4.0 using the
Paragon algorithm with ‘no enzyme’ settings to interrogate an E. coli K12 proteome
database (Uniprot) concatenated with sequences of rOaAEP1b and those of the
three cleavage enzymes, with false discovery rate set at Po0.05. Spectral data for
peptides software matched to rOaAEP1b were confirmed via manual interpretation
in Analyst TF 1.6.
Assaying protease activity against fluorescent peptides. To assay activity of
rOaAEP1b against both internally quenched and other fluorescent peptides,
substrate and enzyme were diluted as appropriate in activity buffer (50mM sodium
acetate, 50mM NaCl, 1mM EDTA, 0.5 mM Tris(2-carboxyethyl)phosphine
hydrochloride, pH 5). To assay activity of rhuLEG (R&D systems) against the same
substrates, the enzyme was first activated by incubation in 50mM sodium acetate,
100mM NaCl, pH 4 (4ml buffer/1 ml enzyme) for 2 h at 37 C. Substrates and
activated rhuLEG were diluted in 50mM MES, 250mM NaCl, pH 5 as required.
Diluted enzyme and substrate were added to black, flat bottomed microtiter plates
in a total assay volume of 110–200 ml. The change in fluorescence intensity over
time was monitored on a SpectraMax M2 (Molecular Devices) using excitation/
emission wavelengths of 320/420 nm (IQF peptides) or 360/460 nm (other
fluorescent peptides). Substrate and enzyme concentrations in each assay and the
time point presented are as indicated in the figure legends.
To determine the kinetics of rOaAEP1b activity against IQF peptides, each
substrate was assayed at a range of concentrations between 2.5 and 80 mM in a total
volume of 200ml. The total protein concentration of the enzyme preparation used
in the kinetic assays was 3.5 mgml 1. It was not possible to precisely determine the
concentration of active enzyme due to impurities remaining in the preparation and
the absence of an inhibitor appropriate for active site titration. However, a
conservative turnover rate (kcat) was estimated based on a mass of 32 kDa and
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the assumption that the total protein concentration reflected active enzyme.
At each substrate concentration, initial velocities were calculated from the linear
portion of the progress curve. Km and Vmax were estimated using the Michaelis–
Menten equation and the curve-fitting program GraphPad Prism (GraphPad
Software, San Diego).
The high peptide concentrations required for estimating kinetic parameters
necessitated the use of a correction factor to account for the inner filter effect; a
phenomenon where high relative concentrations of the quenching group impede
detection of the signal from the fluorescent donor even after substrate hydrolysis48.
This was achieved as described previously48. The output generated by the
fluorescent hydrolysis product (Abz-STRN) was measured in the presence of each
concentration of non-hydrolysed substrate. The correction factor was the ratio
between the expected and observed fluorescence signal at each substrate
concentration. The corrected signal for each data point was then converted to
amount of product by comparison to a standard curve of the fluorescent hydrolysis
product.
Inhibition assays. To investigate the impact of inhibitors on enzyme activity
against the wt IQF peptide, rOaAEP1b (4.4 mgml–1 total protein) was incubated
with the indicated concentration of E64, Ac-YVAD-CHO, pepstatin A and
iodoacetamide for 40min before addition to the substrate (11 mM). Enzyme activity
against the wt IQF peptide was then assessed as described above.
Cyclization assay. Linear target peptides (280 mM) were incubated with
rOaAEP1b (12 mgml 1 total protein unless otherwise indicated) in activity buffer.
The reaction was allowed to proceed for up to 22 h at room temperature and
was analysed by matrix-assisted laser desorption/ionization MS (MALDI MS),
RP-HPLC or NMR as appropriate.
To confirm the presence of cyclic product, R1 derivatives processed by
rOaAEP1b were subsequently digested with endoGlu-C (25 mgml 1) in reaction
buffer (50mM Tris-HCl, 0.5mM Glu–Glu, pH 8) such that the final dilution of the
cyclization mix was 1:4. The reaction was allowed to proceed for 18 h at 37 C
before analysis by MALDI MS.
In heavy water experiments, isotopically labelled water (97 atom % 18O) was
used in place of unlabelled water. Linear target peptides (70mM) were incubated
with rOaAEP1b (6 mgml 1 total protein) in a non-reducing activity buffer (50mM
sodium acetate, 50mM NaCl, 1mM EDTA, pH 5) for 22 h at room temperature.
The final H218O concentration in the assay was 81%.
MS to track cyclization of linear peptides. Cyclization of linear target peptides
was monitored by MALDI MS. The reaction mixture (10–20 ml) was desalted using
C18 zip tips and eluted in 4 ml 50% acetonitrile, 0.1% trifluoroacetic acid (TFA).
A saturated MALDI matrix solution (a–cyano-4-hyroxycinnamic acid) prepared in
95% acetonitrile, 0.1% TFA was diluted 1:22 such that the final matrix solution
comprised 90% acetonitrile, 0.1% TFA and 1mM NH4H2PO4. Eluted samples were
mixed 1:4 with the MALDI matrix, spotted onto a MALDI plate and analysed by an
Ultraflex III TOF/TOF (Bruker) in positive reflector mode.
Purification of kB1 following in vitro cyclization. The crude cyclization mixture
was loaded to an Agilent Zorbax C18 reversed-phase column (4.6 250mm,
300Å) and separated on a Shimadzu Prominence system using a linear gradient of
5–55% buffer B (90% acetonitrile, 10% H2O, 0.05% TFA) in buffer A (0.05%
TFA/H2O) over 60min. Fractions were collected manually, analysed by MALDI
MS essentially as described above and lyophilized. Analytical HPLC and co-elution
studies with chemically synthesized kB1 were carried out as described above.
Nuclear magnetic resonance spectroscopy. All peptides were dissolved in 90%
H2O/10% D2O at a concentration of B2.0mgml 1 (0.5–0.75mM). kB1 obtained
from in vitro cyclizations was dissolved at 0.3mgml 1 (B0.1mM). Spectra were
recorded on a Bruker Avance 600MHz spectrometer equipped with a cryoprobe at
298K. Phase-sensitive mode using time-proportional phase incrementation for
quadrature detection in the t1 dimension was used for all two-dimensional spectra.
Excitation sculpting with gradients was used to achieve water suppression. NMR
experiments included TOCSY using a MLEV-17 spin lock sequence with an 80ms
mixing time, and NOESY with a 200ms mixing time. Spectra were recorded with
4,096 data points in the F2 dimension and 512 increments in the F1 dimension. The
t1 dimension was zero-filled to 1,024 real data points, and the F1 and F2 dimensions
were multiplied by a sine-squared function before Fourier transformation. The
spectra were referenced to the water signal at 4.77 p.p.m. at 298 K. All spectra were
processed using TopSpin (Bruker) and manually assigned with CCPNMR using the
sequential assignment protocol.
Cyclization kinetics. To determine the kinetics of rOaAEP1b activity against the
wt kB1 precursor, the substrate was assayed at room temperature at a range of
concentrations between 75 and 250mM in a total volume of 20–160 ml of activity
buffer. The total protein concentration of the enzyme preparation added to the
kinetic assays was 19.7 mgml 1. The reaction was quenched after 5min with 0.1%
TFA and the volume adjusted to 800ml. A volume of 700 ml was loaded onto a
reversed-phase C18 analytical column (Agilent Eclipse C18, 5 mm, 4.6 150mm)
and peptides were separated by HPLC (19min linear gradient of 12–60% acet-
onitrile, 0.1% TFA at 1mlmin 1). The identity of eluted peaks was confirmed
using MALDI MS. The area under the curve corresponding to the precursor
peptide was quantitated by comparison to a standard curve and initial velocities
were calculated by converting this to mmoles product formed. Kinetic parameters
were estimated using the Michaelis–Menten equation and the curve-fitting pro-
gram GraphPad Prism (GraphPad Software, San Diego). As for the IQF peptides, it
was not possible to precisely determine the concentration of active enzyme due to
impurities remaining in the preparation and the absence of an inhibitor appro-
priate for active site titration. However, a conservative turnover rate (kcat) was
estimated based on a mass of 32 kDa and the assumption that the total protein
concentration reflected active enzyme. Differences in enzyme preparations means
these parameters are not directly comparable to those determined for the IQF
peptides.
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